Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc. (LCTX) is a US-listed equity tracked across major market indices. Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

The company reports trailing twelve-month revenue of $1.73M and net loss of $4.81M. Key metrics include a return on equity of -8.9%, a debt-to-equity ratio of 1.05.

FINOTAUR provides free research summaries, news aggregation, and fundamentals for LCTX to support both active traders and long-term investors.